Core Viewpoint - Jingfeng Medical-B (02675) experienced a significant stock price increase, reaching a new high of 63.75 HKD, reflecting strong market interest in the company and its sector [1] Company Summary - Jingfeng Medical is a leading surgical robot company in China's medical device industry, focusing on the design, development, and manufacturing of surgical robots [1] - It is the first company in China and the second globally to obtain regulatory approval for multi-port, single-port, and natural orifice surgical robots [1] Industry Summary - According to Frost & Sullivan, the penetration rate of surgical robots in China is currently below 1%, significantly lower than the 21.9% in the United States, indicating substantial growth potential [1] - The Da Vinci system currently dominates over 40% of the market share, suggesting that there is considerable room for domestic manufacturers to increase their market presence [1] - The ongoing support from national policies and the acceleration of regulatory approvals are contributing to heightened interest from capital markets in the laparoscopic robot sector [1]